The Saudi Food and Drug Authority (SFDA) is the authority that oversees all drug manufacturing, trade and registration in Saudi Arabia.
Saudi Arabian guidelines for generics
Home/Guidelines
|
Posted 01/07/2011
0
Post your comment
The SFDA is in charge of licensing the manufacture, import, export, distribution, promotion and advertising of medications, as well as assessing the safety, efficacy and quality of medications, and issuing marketing authorisations.
The SFDA also carries out inspections and surveillance of manufacturers, importers, wholesalers and dispensers of medicines; controls promotion and advertising of medicines; and provides independent information on medicines to professionals and the public.
Overarching guidelines
These guidelines cover all generic products:
Guidelines for pharmaceutical equivalence requirements version 1.1
1 September 2010
www.sfda.gov.sa/NR/rdonlyres/C6CC3730-5B8C-4E82-A261-5EEBC71F3D01/0/PharmaceuticalEquivalence_v11.pdf
Bioequivalence guidelines
These guidelines are specifically related to bioequivalence studies for generic products:
The GCC guidelines for bioequivalence version 2
Issue date: 3 February 2011
Implementation date: 3 May 2011
www.sfda.gov.sa/NR/rdonlyres/8369AD75-FD1B-4F57-9253-65FD062AF666/0/TheGCCGuidelinesforBioequivalence_2011.pdf
Related article
Saudi Arabian guidelines for biosimilars
Source: SFDA
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Related content
Regulatory update for post-registration of biological products in Brazil
Home/Guidelines Posted 29/10/2024
FDA interchangeable biosimilars guidance update on revised approach to switching studies
Home/Guidelines Posted 23/07/2024
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment